Definition of clinically distinct molecular subtypes in estrogen receptor-positive breast carcinomas through genomic grade. - Wikidata - awgldk - TriplyDB

Definition of clinically distinct molecular subtypes in estrogen receptor-positive breast carcinomas through genomic grade.

Definition of clinically distinct molecular subtypes in estrogen receptor-positive breast carcinomas through genomic grade.

http://www.wikidata.org/entity/Q42510471

about

DART: Denoising Algorithm based on Relevance network Topology improves molecular pathway activity inference ESR1 is co-expressed with closely adjacent uncharacterised genes spanning a breast cancer susceptibility locus at 6q25.1 Role of thioredoxin reductase 1 and thioredoxin interacting protein in prognosis of breast cancer A population-based gene signature is predictive of breast cancer survival and chemoresponse ZNF703 gene amplification at 8p12 specifies luminal B breast cancer Cooperative interaction between retinoic acid receptor-alpha and estrogen receptor in breast cancer Differential remodeling of actin cytoskeleton architecture by profilin isoforms leads to distinct effects on cell migration and invasion FAM83D promotes cell proliferation and motility by downregulating tumor suppressor gene FBXW7 Differential oestrogen receptor binding is associated with clinical outcome in breast cancer Breast cancer in the personal genomics era Tamoxifen in early-stage estrogen receptor-positive breast cancer: overview of clinical use and molecular biomarkers for patient selection CD36 repression activates a multicellular stromal program shared by high mammographic density and tumor tissues Gene expression profiling identifies activated growth factor signaling in poor prognosis (Luminal-B) estrogen receptor positive breast cancer Squalene epoxidase, located on chromosome 8q24.1, is upregulated in 8q+ breast cancer and indicates poor clinical outcome in stage I and II disease Cancer Hallmarks, Biomarkers and Breast Cancer Molecular Subtypes Genomic profiling in luminal breast cancer Genomic approaches in breast cancer research Utility of prognostic genomic tests in breast cancer practice: The IMPAKT 2012 Working Group Consensus Statement FGFR1 amplification drives endocrine therapy resistance and is a therapeutic target in breast cancer Reconstruction of nuclear receptor network reveals that NR2E3 is a novel upstream regulator of ESR1 in breast cancer TMEM33: a new stress-inducible endoplasmic reticulum transmembrane protein and modulator of the unfolded protein response signaling RCP is a human breast cancer-promoting gene with Ras-activating function Amplification and high-level expression of heat shock protein 90 marks aggressive phenotypes of human epidermal growth factor receptor 2 negative breast cancer Ferroportin and iron regulation in breast cancer progression and prognosis Loss of Rho GDIα and resistance to tamoxifen via effects on estrogen receptor α Molecular portraits: the evolution of the concept of transcriptome-based cancer signatures Cooperative interaction between the MUC1-C oncoprotein and the Rab31 GTPase in estrogen receptor-positive breast cancer cells Amplified loci on chromosomes 8 and 17 predict early relapse in ER-positive breast cancers Respective prognostic value of genomic grade and histological proliferation markers in early stage (pN0) breast carcinoma 'Omic approaches to preventing or managing metastatic breast cancer Supervised risk predictor of breast cancer based on intrinsic subtypes Breast cancer classification and prognostication through diverse systems along with recent emerging findings in this respect; the dawn of new perspectives in the clinical applications.The TGF-β Signaling Regulator PMEPA1 Suppresses Prostate Cancer Metastases to Bone InSilico DB genomic datasets hub: an efficient starting point for analyzing genome-wide studies in GenePattern, Integrative Genomics Viewer, and R/Bioconductor.Wnt signaling in triple negative breast cancer is associated with metastasis Using large-scale molecular data sets to improve breast cancer treatment.Greedy outcome weighted tree learning of optimal personalized treatment rules.Impact of biospecimens handling on biomarker research in breast cancer Integrated analysis of DNA methylation, immunohistochemistry and mRNA expression, data identifies a methylation expression index (MEI) robustly associated with survival of ER-positive breast cancer patients.A comprehensive sensitivity analysis of microarray breast cancer classification under feature variability.

P2860

Q21284334-6D15D1E2-AE31-4F4D-BC14-641CEF1B5984 Q21563388-FACD0436-0638-4188-AD6D-6BD6E362C465 Q22000765-5F0E3341-B5D0-41D5-9BB4-70D0CEC7D419 Q23909226-E1EA09F6-7355-43F8-A636-3C3BC53CB3E4 Q24293333-4D0B64DC-EA69-4FFB-B5E9-CA4F516B5528 Q24295934-1E589D42-9B26-4439-A547-2ABB167B32B2 Q24303907-CEEA0A48-9642-4D82-89E5-6C87C90FAFBC Q24313524-F3267DA6-3991-4513-9A74-01D4E3ACA336 Q24595511-442DFB38-0BE9-46CE-8FAD-79E3BC4D3AB0 Q24602679-95CF3630-7A6A-4D3E-8F44-12FF3A0CEA12 Q24605762-8FF60686-9F65-4E8B-942E-96AB31D278FD Q24633702-8D3FA5B5-59BF-418B-AECC-46A4E352AF88 Q24652481-28F0FC18-6DC5-4215-ABEF-98C138E44AAB Q24655384-96A30755-D0F2-4B9C-9EA3-B13FB3EA030B Q26743510-80F4EA25-85D0-49C8-93DF-90217963875B Q26862681-4455657A-482B-4B6F-87E2-8404673274BC Q26865893-EF4F1E98-7E3D-4E88-9489-430EA5A90DD1 Q27020973-8179BBFC-2A51-4BBC-A5F5-517C1CD9F12B Q27851554-63D7196C-B382-4AA4-A6F0-88D2025045CC Q28114915-800F3CC1-B05A-49D2-9B1F-1E534650E8DB Q28115071-57F6DDCC-D887-4FED-B7AF-FE443D384F76 Q28252569-51AF2BF5-575B-42B2-9D47-7ABA3168F0AF Q28264693-CF3917D5-7EAE-44D6-832F-8F8A0A5DB4A3 Q28289776-7931DA33-09B0-488F-BFE3-1B17B2FC13C8 Q28308069-C6D1963E-6E54-487F-9C8B-D365A2AA9ACB Q28607220-258454BC-93C7-4524-9C8E-A4B1B039E135 Q28727361-4CEFE7D4-700A-49B0-BC83-B9552D0CE724 Q28728499-C869AB45-C035-42BF-83DB-AE7A3A7B81EE Q28730529-4F1CC171-37AD-42C6-A703-F06A07309D0C Q28730572-85110ED5-AD6C-412F-AF35-7215817DF361 Q29617404-5AC29DF5-C19E-4931-B149-866E030DC3D9 Q30245184-91F6AB1B-F618-44F9-9D3F-3F7842B7FB80 Q30299930-C06E3273-99E6-4E47-82A4-97BBB50E837C Q30536439-2C1ECAD6-4FA9-44BE-AE6B-10659648F7D3 Q30597238-E4E0B043-AEDC-4995-8DB4-23F7284B1913 Q30656126-4F947F4C-0208-4A89-AB2C-DD37F90CB2F7 Q30843804-7248506F-F738-4BE5-93A3-5DFD388B3FF0 Q30908463-26B8AFE4-799C-47CD-B241-D5190906434B Q30910707-B8A8320A-9EFB-4706-8D5F-027C91108E2C Q30920662-EB52DEC0-178C-462A-BD50-516D3D2FA387

P2860

Definition of clinically distinct molecular subtypes in estrogen receptor-positive breast carcinomas through genomic grade.

http://www.wikidata.org/entity/Q42510471

description

2007 nî lūn-bûn

@nan

2007年の論文

@ja

2007年学术文章

@wuu

2007年学术文章

@zh-cn

2007年学术文章

@zh-hans

2007年学术文章

@zh-my

2007年学术文章

@zh-sg

2007年學術文章

@yue

2007年學術文章

@zh

2007年學術文章

@zh-hant

name

Definition of clinically disti ...... cinomas through genomic grade.

@en

Definition of clinically disti ...... cinomas through genomic grade.

@nl

type

label

Definition of clinically disti ...... cinomas through genomic grade.

@en

Definition of clinically disti ...... cinomas through genomic grade.

@nl

prefLabel

Definition of clinically disti ...... cinomas through genomic grade.

@en

Definition of clinically disti ...... cinomas through genomic grade.

@nl

P1433

Q42510471-FCE8E3BA-297D-4DF8-AB64-0B64B4B35521

P1476

Q42510471-3A1801C1-4F01-4EA3-AC6F-16FBD6FF1244

P2093

Q42510471-24B2C37C-47F6-4E0A-937C-D9D0685E6806

Q42510471-35C93E2D-DD44-45AB-BC88-52F4C62930EA

Q42510471-3E38B934-23B0-4FDA-B277-B0E35952E746

Q42510471-4F1DD2A1-2EE8-4507-8001-DA59C39F4F40

Q42510471-6CF3C4DE-D7DA-4513-AC00-EAB6A7F33ECC

Q42510471-78C21C32-9056-4BC9-8C0C-7C6FDCE40A4E

Q42510471-7E2F0B71-D9E6-4847-8590-F98007F6B489

Q42510471-B6815FA7-3F61-407F-9C8A-F45B45980C52

Q42510471-BF2BF9AA-AE86-4D0F-9C5A-5CD9DEAF8051

Q42510471-C84F10D1-8E2D-44A5-B7E9-EEDACC7356B0

P304

Q42510471-0AB6156C-D83A-42F5-9796-8C92A07C4B43

P31

Q42510471-2F0BF706-3257-4091-B59D-C18948186AB3

P356

Q42510471-BAF75B9C-D181-4934-B58A-66C9B9616E88

P407

Q42510471-F546EC98-DA0F-40B3-B551-187F41540BC6

P433

Q42510471-BDB44564-5093-4DE0-BE0C-4C9CEBD510CD

P478

Q42510471-F00799C4-6E86-4451-8F65-5C84D89D2F3A

P50

Q42510471-5DDE5103-9426-44DA-8DCA-24559703691B

Q42510471-69261168-5D8A-4BF5-A10A-C3ED2D9A6DE7

Q42510471-AFB1B43F-3891-40C3-AEEF-0B9E42705E51

Q42510471-D4FEA9E9-FBFF-42BD-87FE-17EC44448A0E

Q42510471-DC26A380-5740-4A66-AF88-BDB74DB38E97

P577

Q42510471-66DFC35A-4F3C-4A63-A5DE-0E161D3428B4

P698

Q42510471-9ECE072C-909D-4137-9140-30EFEDD14C87

P356

JCO.2006.07.1522

P1433

Journal of Clinical Oncology

P1476

Definition of clinically disti ...... cinomas through genomic grade.

@en

P2093

Andrew M Tutt

http://www.w3.org/2001/XMLSchema#string

Cheryl Gillet

http://www.w3.org/2001/XMLSchema#string

Christos Sotiriou

http://www.w3.org/2001/XMLSchema#string

Denis Larsimont

http://www.w3.org/2001/XMLSchema#string

Françoise Lallemand

http://www.w3.org/2001/XMLSchema#string

Jan G M Klijn

http://www.w3.org/2001/XMLSchema#string

John A Foekens

http://www.w3.org/2001/XMLSchema#string

Jonas Bergh

http://www.w3.org/2001/XMLSchema#string

Marc Buyse

http://www.w3.org/2001/XMLSchema#string

Martine J Piccart

http://www.w3.org/2001/XMLSchema#string

P304

1239-1246

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1200/JCO.2006.07.1522

http://www.w3.org/2001/XMLSchema#string

P407

P433

10

http://www.w3.org/2001/XMLSchema#string

P478

25

http://www.w3.org/2001/XMLSchema#string

P50

Adrian L Harris

Benjamin Haibe-Kains

Christine Desmedt

Gianluca Bontempi

P577

2007-04-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

17401012

http://www.w3.org/2001/XMLSchema#string